Atossa Therapeutics closes registered direct offering raising USD 4.5 million upfront

Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc.

ATOS

0.00
  • Atossa Therapeutics closed a registered direct offering raising USD 4.5 million in gross proceeds.
  • Deal included 1,363,637 common shares or equivalents, Series A warrants, plus short-term Series B warrants for 1,363,637 shares each.
  • Warrants become exercisable six months from issuance; Series A expires in 5.5 years; Series B expires in 2 years.
  • Full warrant exercise could add about USD 12 million in gross proceeds.
  • Net proceeds earmarked for clinical development, working capital, general corporate purposes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF82960) on June 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.